Author Response: Nerve Growth Factor Receptor Negates the Tumor Suppressor P53 As a Feedback Regulator
Xiang Zhou,Qian Hao,Peng Liao,Shunjing Luo,Min-Hong Zhang,Guohui Hu,Hongbing Liu,Yiwei Zhang,Bo Cao,Melody Baddoo,Erik K. Flemington,Shelya X. Zeng,Hua Lu
DOI: https://doi.org/10.7554/elife.15099.020
2016-01-01
Abstract:Full text Figures and data Side by side Abstract eLife digest Introduction Results Discussion Materials and methods Data availability References Decision letter Author response Article and author information Metrics Abstract Cancer develops and progresses often by inactivating p53. Here, we unveil nerve growth factor receptor (NGFR, p75NTR or CD271) as a novel p53 inactivator. p53 activates NGFR transcription, whereas NGFR inactivates p53 by promoting its MDM2-mediated ubiquitin-dependent proteolysis and by directly binding to its central DNA binding domain and preventing its DNA-binding activity. Inversely, NGFR ablation activates p53, consequently inducing apoptosis, attenuating survival, and reducing clonogenic capability of cancer cells, as well as sensitizing human cancer cells to chemotherapeutic agents that induce p53 and suppressing mouse xenograft tumor growth. NGFR is highly expressed in human glioblastomas, and its gene is often amplified in breast cancers with wild type p53. Altogether, our results demonstrate that cancers hijack NGFR as an oncogenic inhibitor of p53. https://doi.org/10.7554/eLife.15099.001 eLife digest Cancer often develops as a result of alterations to “tumor suppressor” genes within cells. This results in the cells growing and dividing too much, which causes a tumor to form. One of the most important tumor suppressor genes produces a protein called p53, which is lost or mutated in roughly half of all human cancers. In the other half of cancers p53 itself is normal, but is often disabled by proteins that promote tumor growth. One of the remaining challenges in the field of cancer research is to identify which proteins inhibit p53 directly. Identifying these proteins would help clarify why many human cancers, such as some brain cancers, breast and skin cancers, often maintain a normal form of the p53 tumor suppressor protein. Zhou et al. now provide evidence that shows that a protein called nerve growth factor receptor (NGFR) is one such protein. NGFR was known to be important for the healthy development of the brain and nervous system. Unexpectedly, however, Zhou et al. found that NGFR binds directly to p53 and disables it in several types of human cancer cells. This finding is likely to be important because NGFR is produced in abnormally high amounts in several human cancer types, including skin, breast, bone and some brain cancers. Reducing the levels of NGFR in cancer cells caused the cells to become more sensitive to some anti-cancer drugs. Overall, the results presented by Zhou et al. suggest that developing new drugs that target NGFR could produce new treatments for human cancers that have a normal form of the gene that produces p53. More experiments are also needed to find out whether NGFR has other ways of promoting the development of cancerous tumors. https://doi.org/10.7554/eLife.15099.002 Introduction Tumorigenesis is highly associated with inactivation of the tumor suppressor p53, as it is mutated in ~50% of all types of human cancers, and its functions are impaired through various mechanisms in the rest of human cancers (Levine and Oren, 2009). p53 executes its tumor suppressive function mainly by inducing the expression of a large number of genes involved in cell cycle control, senescence, apoptosis, ferroptosis, autophagy, and metabolism (Jiang et al., 2015; Kruiswijk et al., 2015). Because of the detrimental effects of p53 on normal cells, the cells have developed mechanisms to monitor its activity, which are often hijacked by cancer cells. One key monitor of p53 is MDM2 (HDM2 in human), an oncoprotein encoded by a p53 transcriptional target gene that is amplified or overexpressed in several human tumors (Fakharzadeh et al., 1991; Momand et al., 1992; Oliner et al., 1992, 1993; Wu et al., 1993). MDM2 inhibits p53 activity primarily by binding to and concealing the N-terminal transcriptional activation (TA) domain of p53 (Oliner et al., 1993) and by mediating its poly-ubiquitination and proteolysis (Fuchs et al., 1998; Haupt et al., 1997; Kubbutat et al., 1997). Genetically, disruption of the TP53 gene completely rescues the lethal phenotype of Mdm2 knockout mice (Jones et al., 1995; Montes de Oca Luna et al., 1995). A myriad of stresses can orchestrate this MDM2-p53 feedback loop. The ARF tumor suppressor directly associates with MDM2 and inhibits MDM2-mediated p53 ubiquitination and degradation upon oncogenic stress (Palmero et al., 1998; Zhang et al., 1998; Zindy et al., 1998). Also, several ribosomal proteins boost p53 activation by untying the MDM2-p53 loop in response to ribosomal or nucleolar stress (Zhang and Lu, 2009; Zhou et al., 2012, 2015a). But, oncogenic proteins can enhance MDM2 E3 ligase activity towards p53. MDMX (also called MDM4), the MDM2 homologue, can enhance MDM2-mediated p53 proteasomal degradation by binding to MDM2, besides directly interacting with p53 and repressing its activity (Shvarts et al., 1996). High expression of MDM2 and MDMX in several cancers, such as breast cancer and melanoma, is often considered as the reason why these cancers sustain wild type (wt) p53 (Wade et al., 2013), but this could only account for a portion of wt p53-harboring cancers. Thus, it is still unknown if there are other proteins that can also suppress p53 function in the remaining cancers. In this study, we revealed a novel feedback regulation of p53 by nerve growth factor receptor (NGFR, also called p75NTR or CD271). NGFR is a 75 kD single-transmembrane protein without kinase activity and widely expressed in the central and peripheral nervous system (Barker, 2004). Often partnering with other receptors, such as TrkA, it is involved in a multitude of processes during neurogenesis, such as neural cell death, neuronal differentiation, neurite growth, and synaptic plasticity (Barker, 2004). Also, the NGF-NGFR cascade activates NF-κB, leading to inhibition of apoptosis (Carter et al., 1996) and increased survival of schwannoma (Ahmad et al., 2014; Gentry et al., 2000) and breast cancer cells (Descamps et al., 2001). In addition, overexpression of NGFR observed in many metastatic cancers promotes tumor migration and invasion (Boiko et al., 2010; Civenni et al., 2011; Johnston et al., 2007). But, in prostate and bladder cancers, NGFR appears to suppress tumor growth and/or metastasis (Krygier and Djakiew, 2002; Tabassum et al., 2003). It remains largely elusive why and how NGFR plays opposite roles in the context of different cancers. These studies together with our initial findings that p53 binds to the NGFR promoter and induces its expression in cancer cells motivated us to further explore the functional interplay between NGFR and p53, and its role in cancer development. As detailed below, we surprisingly found that NGFR inactivates p53 by directly binding to its central DNA-binding domain and preventing its association with its target promoters and by enhancing its MDM2-mediated ubiquitination and proteolysis. This function is ligand-independent because it occurred in the nucleus and without ligand treatment of cancer cells. Biologically, cancer cells hijack the negative feedback regulation of p53 by NGFR to their growth advantage, as down regulation of NGFR induced p53-dependent apoptosis and cell growth arrest as well as suppressed tumor growth. Furthermore, NGFR was found to be highly expressed in 68.75% (33/48) of human gliomas examined. Consistently, NGFR is amplified in breast cancers that harbor wt TP53 based on the TCGA database (Cerami et al., 2012; Gao et al., 2013). Hence, our discovery of NGFR as another feedback suppressor of p53 could explain why some cancers sustain wt p53 and also suggest NGFR as a potential target for the development of new anti-cancer therapy. Results NGFR is a bona fide transcriptional target of p53 From our previous studies to assess the global effects of Inauhzin (INZ) on p53 pathway in cancer cells (Zhang et al., 2012, 2014; Liao et al., 2012), we identified NGFR as a potential p53-regulated gene. To confirm this result, we treated three types of p53-containing cancer cell lines (HCT116p53+/+, H460 and HepG2) with INZ, Doxorubicin (Dox) and 5-Fluorouracil (5-FU). The expression of NGFR mRNA was drastically elevated by all the three agents (Figure 1A,B and C). Consistently, NGFR protein level increased in response to Dox or 5-FU treatment in p53-intact, but not p53-null (HCT116p53-/-) or mutated (PCL/PRF/5), cancer cells (Figure 1D and E). Consistently, ectopic wt, but not mutant, p53 induced NGFR mRNA expression in p53-deficient H1299 and HCT116p53-/- cells (Figure 1F and G). Conversely, knockdown of p53 markedly reduced NGFR mRNA level (Figure 1H and I). These results demonstrate that anti-cancer drug-induced NGFR expression in the cells is p53-dependent. Figure 1 Download asset Open asset p53 transcriptionally induces NGFR expression in cancer cells. (A,B,C) NGFR mRNA expression is elevated by p53-inducing agents. HCT116 p53+/+ (A) H460 (B) and HepG2 (C) cells were treated with Inauhzin, Doxorubicin or 5-Fluorouracil for 15 h, and NGFR expression was determined by q-PCR (Mean ± SEM, n = 3). Three biological replicates (independent experiments) and a two-tailed t-test were used for P value calculation, p*<0.01. Most q-PCR were performed by three biological replicates, each including three technical replicates. (D) NGFR protein expression is elevated by p53-inducing agents in colon cancer cell lines. HCT116 p53+/+ and HCT116 p53-/- cells were treated with Doxorubicin or 5-Fluorouracil for 15 hr followed by IB using antibodies as indicated. (E) NGFR protein expression is elevated by p53-inducing agents in liver cancer cell lines. HepG2 and PLC/PRF/5 cells were treated with Doxorubicin or 5-Fluorouracil for 15 hr followed by IB using antibodies as indicated. (F,G) NGFR mRNA expression is induced by ectopic wild-type, but not mutant, p53. HCT116 p53-/- (F) and H1299 (G) cells were transfected with wild-type or mutant p53 for 30 hr and NGFR expression was determined by q-PCR (Mean ± SEM, n = 3). Three biological replicates were used for p value, p*<0.01. (H,I) NGFR mRNA expression is inhibited by p53 knockdown. HCT116 p53+/+ (H) and H460 (I) cells were transfected with p53 or control siRNA for 72 hr, and Doxorubicin or 5-Fluorouracil was supplemented 15 hr before the cells were harvested for q-PCR (Mean ± SEM, n = 3). Three biological replicates were used for p value, p*<0.05. (J) A schematic of predicted p53 responsive elements in the NGFR promoter. (K,L) p53 induces luciferase activity through RE1. Luciferase assay was performed using H1299 and U2OS cells as described in Materials and methods (Mean ± SEM, n = 3 biological replicates). (M,N) p53 is associated with the NGFR promoter. HCT116 p53+/+ cells were treated with or without Doxorubicin for 15 hr followed by ChIP assay using anti-p53 or mouse IgG. https://doi.org/10.7554/eLife.15099.003 Next, we identified two potential p53 responsive DNA elements (RE) in the NGFR promoter by bioinformatics analysis, RE1 and RE2, at −4826 bp and –6516 bp upstream from the transcriptional initiation site, respectively (Figure 1J). The RE1 was responsive to p53, as ectopic p53 markedly activated luciferase reporter expression through RE1, but not RE2, in H1299 (Figure 1K) and U2OS (Figure 1L) cells. This result was validated by chromatin-associated immunoprecipitation (ChIP) assays after treating HCT116 p53+/+ cells with or without Dox. Endogenous p53 specifically associated with the RE1-containing NGFR promoter, but not a non-related promoter; this association was enhanced by Dox treatment (Figure 1M and N). Thus, these results demonstrate that NGFR is a bona fide transcriptional target of p53. NGFR is required for cancer cell survival and clonogenicity Previous studies showed that NGFR induces apoptosis in some cancer cells, but promotes cell survival and growth in other cancer cells (Molloy et al., 2011). Thus, we re-determined the role of NGFR in cancer cell growth and proliferation and whether this role is p53-dependent. Surprisingly, knockdown of NGFR elicited significant apoptosis of H460 (Figure 2A and B) and HCT116 p53+/+ (Figure 2C and D) cells as measured by flow cytometric analyses, consequently reducing cell viability during the 4-day culture (Figure 2E and F). To verify if NGFR supports tumor cell growth and proliferation and to see if this role is p53-dependent, we performed colony formation assays by knocking down NGFR in p53-containing H460 and p53-deficient H1299 cancer cells (Figure 2—figure supplement 1A). NGFR ablation more dramatically repressed the colony formation of H460 cells than that of H1299 cells (Figure 2G). This result suggests that NGFR may support cancer cell survival through both p53-dependent and independent mechanisms. Since NGFR was found to be required for nerve growth factor-mediated NF-κB activation (Carter et al., 1996), knockdown of NGFR in H1299 may impair NF-κB activation, thus leading to partially restrained cell viability and reduced colonies. Additionally, immunohistochemical (IHC) staining of human gliomas and their adjacent normal tissues exhibited hyperexpression of NGFR in the tumor tissues (Figure 2H and Figure 2—figure supplement 1B). Consistently, NGFR was more highly expressed in human glioma tissues compared to adjacent tissues as determined by immunoblotting (IB) (Figure 2I). Taken together, these results suggest that NGFR promotes cancer cell growth and proliferation, likely in part by inactivating p53. Figure 2 with 1 supplement see all Download asset Open asset NGFR is required for cancer cell survival and clonogenicity, and highly expressed in glioma. (A) NGFR knockdown induces apoptosis of H460 cells. Cells were transfected with NGFR or control siRNA for 72 to 96 hr, and Doxorubicin was supplemented 15 hr before the cells were harvested for flow cytometry analyses. (B) Quantification of Sub-G1 population in (A) (Mean ± SEM, n = 3). Three biological replicates were used for p value, p*<0.05. (C) NGFR knockdown induces apoptosis of HCT116 p53+/+cells. Cells were transfected with NGFR or control siRNA for 72 to 96 hr, and Doxorubicin was supplemented 15 hr before the cells were harvested for flow cytometry analyses. (D) Quantification of Sub-G1 population in (C) (Mean ± SEM, n = 2). Three biological replicates were used for p value, p*<0.05. (E, F) NGFR knockdown suppresses cell survival. H460 (E) and HCT116 p53+/+ (F) cells were transfected with NGFR or control siRNA and seeded in 96-well plate the next day (Day 1). Cell viability was evaluated every 24 hr (Mean ± SEM, n = 3). Three biological replicates were used for p value, p*<0.05. (G) NGFR knockdown inhibits clonogenicity. H460 and H1299 cells were transfected with NGFR or control siRNA and seeded in 10-cm plates the next day. Colonies were fixed by methonal and stained with crystal violet solution (left panel). Quantification of colonies is shown in the right panel (Mean ± SEM, n = 2). Two biological replicates were used for p value, p*<0.05. (H) IHC analyses of human glioma and the adjacent noncancerous tissues. (I) IB analyses of human glioma and the adjacent noncancerous tissues (left panel). Quantification of NGFR expression (right panel) (Mean ± SEM, n = 48, p*<0.01). https://doi.org/10.7554/eLife.15099.004 NGFR inactivates p53 by enhancing its MDM2-mediated ubiquitination and proteolysis To test if NGFR negates p53 activity, we first checked if NGFR affects p53 protein level in H460 cells that were treated with Dox or 5-FU. Indeed, p53 level induced by Dox or 5-FU was markedly reduced by ectopic NGFR (Figure 3A). Inversely, knockdown of NGFR strikingly elevated the level of endogenous p53 and that of its target genes p21 and PUMA in human p53-containing H460, HepG2, neuroblastoma SK-N-SH, melanoma SK-MEL-103 and SK-MEL-147 and HCT116 p53+/+ cell lines (Figure 3B), whereas did not affect PUMA expression in HCT116 p53-/- cells (Figure 3—figure supplement 1). Consistently, knockdown of NGFR led to the global expression of a group of known p53 target genes, as measured by RNA-seq analysis in H460 cells (Figure 3C). This result was further confirmed by utilizing a second siRNA (siNGFR#2), as NGFR knockdown by this siRNA also induced the protein level of p53 and the mRNA levels of its target genes, including BAX, BTG2, MDM2, p21, and PUMA (Figure 3D). Also, ablation of NGFR prolonged p53’s half-life (Figure 3E), suggesting that NGFR might regulate the stability of p53. Next, we tested if NGFR affects MDM2-induced p53 ubiquitination by conducting a p53 ubiquitination assay in H1299 cells with ectopic proteins. Surprisingly, ectopic NGFR enhanced MDM2-mediated p53 ubiquitination in a dose-dependent manner (Figure 3F), although this protein was found to mainly reside in the cytoplasmic membrane (Barker, 2004). Consistently, NGFR also enhanced MDM2-mediated p53 proteasomal degradation, which was abolished by the proteasome inhibitor MG132 (Figure 3G). Without MDM2, NGFR was unable to alter p53 protein level in cells (Figure 4). Altogether, these results indicate that NGFR reduces p53 stability by enhancing its MDM2-mediated ubiquitination and degradation. Figure 3 with 1 supplement see all Download asset Open asset NGFR suppresses p53 activity by enhancing MDM2-mediated ubiquitination and proteasomal degradation. (A) NGFR inhibits p53 activation by Doxorubicin or 5-Fluorouracil. H460 cells were transfected with NGFR for 30 hr and treated with Doxorubicin or 5-Fluorouracil for 15 hr before harvested for IB using antibodies as indicated. (B) NGFR knockdown induces p53 expression and activity. A panel of cancer cell lines were transfected with NGFR or control siRNA followed by IB using antibodies as indicated. The values in the rightmost panel indicate the p53/β-actin ratios. (C) NGFR knockdown induces p53 target gene expression. H460 cells were transfected with NGFR or control siRNA followed by RNA-sequencing analyses. Genes with over 1.5-fold increase in expression were shown (Three biological replicates were used for p value, p<0.05. (D) Two siRNAs targeting different sequences were used for knocking down NGFR in H460 cells. The expression of p53 target genes was assessed by q-PCR (Mean ± SEM, n = 2 biological replicates), while p53 expression was detected by IB. Validation of NGFR knockdown by the two siRNAs is shown in the right corner. (E) NGFR knockdown prolongs p53’s half-life. H460 cells transfected with NGFR or control siRNA for 72 hr were treated with 100 µg/ml of CHX and harvested at the time points as indicated. IB was performed using antibodies as indicated (upper panel) and quantification of p53/β-actin ratio is shown in the lower panel. (F) NGFR promotes MDM2-induced p53 ubiquitination. H1299 cells were transfected with combinations of plasmids encoding p53, HA-MDM2, Myc-NGFR or His-Ub and treated with MG132 6 hr before harvested for in vivo ubiquitination assay. Bound proteins and inputs were detected by IB using antibodies as indicated. (G) NGFR enhancesMDM2-mediated p53 proteasomal degradation. H1299 cells were transfected with combinations of plasmids encoding p53, HA-MDM2 or RFP-NGFR followed by IB using antibodies as indicated. MG132 was supplemented to the medium for 6 hr. https://doi.org/10.7554/eLife.15099.006 Figure 4 with 1 supplement see all Download asset Open asset NGFR inactivates p53 independently of MDM2. (A) NGFR interacts with p53 in the absence of MDM2. MEF p53-/-;Mdm2-/- cells were transfected with plasmids encoding Myc-NGFR or p53 followed by co-IP-IB assays using antibodies as indicated. (B) NGFR does not affect p53 protein expression in the absence of MDM2. MEF p53-/-;Mdm2-/- cells were transfected with combinations of plasmids encoding Myc-NGFR, HA-MDM2 or p53 followed by IB using antibodies as indicated. (C) NGFR represses p53-induced luciferase activity independently of MDM2. MEF p53-/-;Mdm2-/- cells were transfected with plasmids as indicated in the figure and luciferase assay was performed as described in Materials and methods (Mean ± SEM, n = 3). Three biological replicates were used for p value, p*<0.05. (D) NGFR inhibits p53-induced target gene expression independently of MDM2. MEF p53-/-;Mdm2-/- cells were transfected with plasmids as indicated in the figure followed by q-PCR analysis (Mean ± SD, n = 3). Three technical replicates were used for p value, p*<0.05. (E) NGFR impedes p53 association with the p21 promoter in H1299 cells. Cells were transfected with plasmids as indicated and treated with MG132 for 6 hr before harvested for ChIP-PCR analyses. (F) NGFR impedes p53 association with the p21 and Bax promoters independently of MDM2. MEF p53-/-;Mdm2-/- cells were transfected with plasmids as indicated followed by ChIP-PCR analyses. https://doi.org/10.7554/eLife.15099.008 NGFR regulates p53 stability by binding to MDM2 Next, we tested if NGFR interacts with MDM2 by conducting a set of reciprocal co-immunoprecipitation (co-IP) assays. Indeed, ectopic NGFR bound to ectopic MDM2, and vice versa (Figure 5A). We then mapped their binding domains by performing a set of co-IP and GST-pull down assays. NGFR was specifically pulled down with the C-terminal aa 284–491 fragment, but not N-terminal fragments, of MDM2, which encompasses the zinc-finger, acidic, and ring-finger domains, in H1299 cells (Figure 5C). This result was verified by in vitro GST-pull down assays (Figure 5D). Using the same approach, we also mapped the MDM2-binding domain of NGFR. Unexpectedly, MDM2 interacted with the N-terminal extracellular and transmembrane domain, but not the C-terminal cytoplasmic domain, of NGFR (Figure 5E). Also, we validated the interaction between endogenous NGFR and MDM2 in human neuroblastoma SK-N-SH cells that sustains high level of NGFR (Figure 5H). To determine if this interaction takes place in the nucleus, we used H460 cells stably expressing NGFR, HCT116 p53+/+ and SK-MEL-147 cells, fractionated them, and conducted IB assays. Indeed, full-length NGFR was present in both cytoplasm and nucleus (Figure 5—figure supplement 1A–C). Consistently, confocal microscopy analysis revealed that NGFR is present in all of the cellular compartments of SK-MEL-147 cells, albeit with less intensity in the nucleus than that in the cytoplasm (Figure 5—figure supplement 1D). Of note, the nuclear and cytoplasmic levels of NGFR increased upon Dox treatment likely due to p53 activation (Figure 5—figure supplement 1D). Also, NGFR was co-immunoprecipitated with MDM2 from the nuclear extracts of NGFR-stably expressed H460 (Figure 5I) and SK-MEL-147 cells in a reciprocal pattern (Figure 5J). Hence, these results demonstrate that the N-terminus of NGFR binds to the C-terminus of MDM2, and this interaction occurs in the nucleus. Figure 5 with 1 supplement see all Download asset Open asset NGFR interacts with MDM2 in the nucleus. (A,B) NGFR interacts with MDM2. H1299 cells were transfected with plasmids encoding Myc-NGFR, Flag-MDM2 or HA-MDM2 followed by co-IP-IB assays using antibodies as indicated. (C) Mapping the NGFR binding domain on MDM2 by co-IP-IB assays. H1299 cells were transfected with the plasmid encoding V5-tagged MDM2 fragment, aa 1–150, aa 1–301 or aa 284–491, along with the Myc-NGFR-encoded plasmid. Co-IP-IB assays were performed using antibodies as indicated. (D) Mapping the NGFR binding domain on MDM2 by GST-pull down assay. The prokaryotic expressed GST-tagged MDM2 fragment, aa 1–150, aa 1–301 or aa 284–491, or GST protein alone was incubated with cell lysates overexpressing Myc-NGFR. Bound proteins were detected by IB using anti-NGFR or coomassie staining. (E) Mapping the MDM2 binding domain on NGFR. H1299 cells were transfected with the plasmid encoding Myc-tagged NGFR fragment, aa 1–272 or aa 273–427, along with the Flag-MDM2-encoded plasmid. Co-IP-IB assays were performed using antibodies as indicated. (F) A schematic of NGFR binding region on MDM2. (G) A schematic of MDM2 binding region on NGFR. (H) Endogenous interaction of NGFR and MDM2 in SK-N-SH cells. Cells treated with Doxorubicin for 12 hr and MG132 for 6 hr were harvested for co-IP-IB assays using antibodies as indicated. (I,J,K) NGFR interacts with both MDM2 and p53 in the nucleus. Nuclear fractions from NGFR-stably expressed H460 (I) and SK-MEL-147 cells (J,K) were subjected to co-IP-IB assays using antibodies as indicated. https://doi.org/10.7554/eLife.15099.010 NGFR interacts with p53 While testing the endogenous NGFR-MDM2 binding, we also detected p53 in the NGFR-MDM2 complex (Figure 5H–K). Thus, we tested if p53 binds to NGFR directly or indirectly through MDM2. First, we conducted co-IP-IB and GST-Pull down assays. Indeed, NGFR and p53 co-immunoprecipitated with each other in reciprocal co-IP-IB assays (Figure 6A–B). Further confirming this interaction was the mapping of the NGFR-binding domain to the central DNA-binding domain of p53 using a similar co-IP-IB assay by transfecting plasmids encoding individual p53 fragments together with NGFR plasmid into H1299 cells (Figure 6C). This mapping was validated by a GST-pull down assay using purified GST-p53 fusion proteins with different p53 fragments. NGFR specifically bound to the full-length p53 and its central DNA-binding domain (aa 101–300) (Figure 6D). This finding explained why NGFR, MDM2 and p53 could form a ternary complex (Figure 5H–k). We also mapped the p53-binding domain of NGFR by conducting a set of co-IP-IB assays. Like MDM2, p53 also bound to the N-terminal region of NGFR (Figure 6E). Together with the result showing that NGFR binds to p53 in the nucleus (Figure 5I–K), these results demonstrate that the N-terminus of NGFR binds to the central DNA-binding domain of p53, and this interaction also occurs in the nucleus. Figure 6 Download asset Open asset NGFR interacts with p53 in the nucleus. (A, B) NGFR interacts with p53. H1299 cells were transfected with plasmids encoding Myc-NGFR, Flag-p53 or p53 followed by co-IP-IB assays using antibodies as indicated. (C) Mapping the NGFR binding domain on p53 by co-IP-IB assays. H1299 cells were transfected with the plasmid encoding flag-tagged p53 fragment, aa 1–300, aa 101–300, aa 101–393 or aa 301–393, along with the Myc-NGFR-encoded plasmid. Co-IP-IB assays were performed using antibodies as indicated. (D) Mapping the NGFR binding domain on p53 by GST-pull down assay. The prokaryotic expressed GST-tagged full-length p53 or p53 fragment, aa 1–73, aa 100–290 or aa 291–393, or GST protein alone was incubated with cell lysates overexpressing Myc-NGFR. Bound proteins were detected by IB using anti-NGFR or coomassie staining. (E) Mapping the p53-binding domain on NGFR. H1299 cells were transfected with the plasmid encoding Myc-tagged NGFR fragment, aa 1–272 or aa 273–427, along with the V5-p53-encoded plasmid. Co-IP-IB assays were performed using antibodies as indicated. (F) A schematic of NGFR binding region on p53. (G) A schematic of p53 binding region on NGFR. https://doi.org/10.7554/eLife.15099.012 NGFR attenuates p53 activity independently of MDM2 The finding that NGFR binds to the central DNA-binding domain of p53 suggests that this protein might directly regulate p53 transcriptional activity independently of MDM2. To test this idea, we first determined if NGFR can bind to p53 in the absence of MDM2 by introducing their expression plasmids alone or together into MEFMdm2-/-;p53-/- cells followed by co-IP-IB assays. Indeed, NGFR was co-immunoprecipitated with p53 in these cells (Figure 4A). Interestingly and as also mentioned above, ectopic NGFR at different doses failed to decrease the level of ectopic p53 in MEFMdm2-/-;p53-/- cells (Figure 4B), suggesting that NGFR cannot directly degrade p53 without MDM2. Then, we tested if NGFR could regulate p53 transcriptional activity in the absence of MDM2 by performing luciferase reporter assays. Interestingly, ectopic NGFR inhibited p53-induced luciferase activity driven by the miR-34a promoter in MEFMdm2-/-;p53-/- cells in a dose dependent fashion (Figure 4C). Also, NGFR repressed ectopic p53-induced expression of p21 and Puma in MEFMdm2-/-;p53-/- cells (Figure 4D). Consistently, ectopic NGFR markedly reduced the association of p53 with the endogenous p21 and Bax promoters in these cells as analyzed by ChIP assays in H1299 or MEFMdm2-/-;p53-/- cells (Figure 4E). Since MDMX, the partner of MDM2, also bound to NGFR (Figure 4—figure supplement 1A), MEFMdm2-/-; Mdmx-/-; p53-/- cells were used to determine if MDMX is required for p53 inactivation by NGFR. NGFR still inhibited p53 activity as measured by p21 and Puma expression (Figure 4—figure supplement 1B). Collectively, these results demonstrate that NGFR also inhibits p53 by directly binding to its central DNA-binding domain and preventing its association with its target promoter. Depletion of NGFR sensitizes tumor cells to cisplatin and doxorubicin The discovery that NGFR is an inhibitor of p53 in cancer cells suggested the possibility of that depletion of this protein could sensitize cancer cells to chemotherapeutic agents. We tested this idea by treating H460 and SK-N-SH cells with different doses of Dox and Cisplatin after introducing control or NGFR siRNAs into the cells. Indeed, both of the chemotherapeutic drugs induced p53 and its target PUMA or p21 more apparently when the cells were transfected with NGFR siRNA compared to those with control siRNA in
What problem does this paper attempt to address?
-
Nerve Growth Factor Receptor Negates the Tumor Suppressor P53 As a Feedback Regulator.
Xiang Zhou,Qian Hao,Peng Liao,Shiwen Luo,Minhong Zhang,Guohui Hu,Hongbing Liu,Yiwei Zhang,Bo Cao,Melody Baddoo,Erik K. Flemington,Shelya X. Zeng,Hua Lu
DOI: https://doi.org/10.7554/elife.15099
IF: 7.7
2016-01-01
eLife
Abstract:Cancer develops and progresses often by inactivating p53. Here, we unveil nerve growth factor receptor (NGFR, p75NTR or CD271) as a novel p53 inactivator. p53 activates NGFR transcription, whereas NGFR inactivates p53 by promoting its MDM2-mediated ubiquitin-dependent proteolysis and by directly binding to its central DNA binding domain and preventing its DNA-binding activity. Inversely, NGFR ablation activates p53, consequently inducing apoptosis, attenuating survival, and reducing clonogenic capability of cancer cells, as well as sensitizing human cancer cells to chemotherapeutic agents that induce p53 and suppressing mouse xenograft tumor growth. NGFR is highly expressed in human glioblastomas, and its gene is often amplified in breast cancers with wild type p53. Altogether, our results demonstrate that cancers hijack NGFR as an oncogenic inhibitor of p53.
-
Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers
Jayanthi P. Gudikote,Tina Cascone,Alissa Poteete,Piyada Sitthideatphaiboon,Qiuyu Wu,Naoto Morikawa,Fahao Zhang,Shaohua Peng,Pan Tong,Lerong Li,Li Shen,Monique Nilsson,Phillip Jones,Erik P. Sulman,Jing Wang,Jean-Christophe Bourdon,Faye M. Johnson,John Heymach
DOI: https://doi.org/10.1016/j.jbc.2021.101163
IF: 5.485
2021-01-01
Journal of Biological Chemistry
Abstract:Inactivation of p53 is present in almost every tumor, and hence, p53-reactivation strategies are an important aspect of cancer therapy. Common mechanisms for p53 loss in cancer include expression of p53-negative regulators such as MDM2, which mediate the degradation of wildtype p53 (p53 alpha), and inactivating mutations in the TP53 gene. Currently, approaches to overcome p53 deficiency in these cancers are limited. Here, using non-small cell lung cancer and glioblastoma multiforme cell line models, we show that two alternatively spliced, functional truncated isoforms of p53 (p53 beta and p53 gamma , comprising exons 1 to 9 beta or 9 gamma , respectively) and that lack the C-terminal MDM2-binding domain have markedly reduced susceptibility to MDM2-mediated degradation but are highly susceptible to nonsense-mediated decay (NMD), a regulator of aberrant mRNA stability. In cancer cells harboring MDM2 overexpression or TP53 mutations downstream of exon 9, NMD inhibition markedly upregulates p53 beta and p53 gamma and restores activation of the p53 pathway. Consistent with p53 pathway activation, NMD inhibition induces tumor suppressive activities such as apoptosis, reduced cell viability, and enhanced tumor radiosensitivity, in a relatively p53-dependent manner. In addition, NMD inhibition also inhibits tumor growth in a MDM2-overexpressing xenograft tumor model. These results identify NMD inhibition as a novel therapeutic strategy for restoration of p53 function in p53-deficient tumors bearing MDM2 over expression or p53 mutations downstream of exon 9, subgroups that comprise approximately 6% of all cancers.
-
Ninjurinl, A Target Of P53, Modulates P53-Dependent Tumor Suppression In Vivo
Hee Jung Yang,Seong Jun Cho,Jin Zhang,Wensheng Yan,Xinbin Chen
DOI: https://doi.org/10.1158/1538-7445.AM2016-675
IF: 11.2
2016-01-01
Cancer Research
Abstract:The nerve injury-induced protein 1 (Ninjurin1, Ninj1), a homophilic adhesion molecule, is involved in nerve regeneration, inflammation and vascular regression. Ninj1 is found to be overexpressed in human cancers including hepatocellular carcinoma and acute lymphoblastic leukemia. However, the role of Ninj1 in tumorigenesis has not been elucidated. Recently, we found that Ninj1 is transcriptionally regulated by p53, which in turn regulates p53 expression through mRNA translation. Thus, the mutual regulation between p53 and Ninj1 represents a novel loop in the p53 pathway. To examine the biological significance of the p53-Ninj1 loop, we generated and monitored 4 cohorts of mice: (i) WT, (ii) Ninj1-het, (iii) p53-null, (iv) Ninj1-het; p53-null. We found that Ninj1-het mice were highly prone to skin lesions. We also found that Ninj1 deficiency shortened the life-span but decreased the incidence of sarcoma in mice without p53. Additionally, we found that Ninj1-het; p53-null mice were prone to hydrocephalus and kidney abnormality. To examine the association of Ninj1 with mutant p53, we generated and characterized Ninj1+/-; p53 R270H/- and p53 R270H/- mice. We found that Ninj1 deficiency shortened the life-span and promoted the frequency and aggressiveness of tumors in p53 R270H/- mice. Together, we conclude that Ninj1 differently regulates the tumor susceptibility in a p53-dependent manner in vivo and that the Ninj1-p53 loop plays a pivotal role in tumor suppression and longevity. Citation Format: Hee Jung Yang, Seong Jun Cho, Jin Zhang, Wensheng Yan, Xinbin Chen. Ninjurin1, a target of p53, modulates p53-dependent tumor suppression in vivo . [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 675.
-
Abstract 675: Ninjurin1, a Target of P53, Modulates P53-Dependent Tumor Suppression in Vivo
Hee Jung Yang,Seong Jun Cho,Jin Zhang,Wensheng Yan,Xinbin Chen
DOI: https://doi.org/10.1158/1538-7445.am2016-675
IF: 11.2
2016-01-01
Cancer Research
Abstract:Abstract The nerve injury-induced protein 1 (Ninjurin1, Ninj1), a homophilic adhesion molecule, is involved in nerve regeneration, inflammation and vascular regression. Ninj1 is found to be overexpressed in human cancers including hepatocellular carcinoma and acute lymphoblastic leukemia. However, the role of Ninj1 in tumorigenesis has not been elucidated. Recently, we found that Ninj1 is transcriptionally regulated by p53, which in turn regulates p53 expression through mRNA translation. Thus, the mutual regulation between p53 and Ninj1 represents a novel loop in the p53 pathway. To examine the biological significance of the p53-Ninj1 loop, we generated and monitored 4 cohorts of mice: (i) WT, (ii) Ninj1-het, (iii) p53-null, (iv) Ninj1-het; p53-null. We found that Ninj1-het mice were highly prone to skin lesions. We also found that Ninj1 deficiency shortened the life-span but decreased the incidence of sarcoma in mice without p53. Additionally, we found that Ninj1-het; p53-null mice were prone to hydrocephalus and kidney abnormality. To examine the association of Ninj1 with mutant p53, we generated and characterized Ninj1+/-; p53 R270H/- and p53 R270H/- mice. We found that Ninj1 deficiency shortened the life-span and promoted the frequency and aggressiveness of tumors in p53 R270H/- mice. Together, we conclude that Ninj1 differently regulates the tumor susceptibility in a p53-dependent manner in vivo and that the Ninj1-p53 loop plays a pivotal role in tumor suppression and longevity. Citation Format: Hee Jung Yang, Seong Jun Cho, Jin Zhang, Wensheng Yan, Xinbin Chen. Ninjurin1, a target of p53, modulates p53-dependent tumor suppression in vivo. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 675.
-
Abstract P1-08-01: Regulation of Estrogen Receptor-Α by NF1
Z-Y Zheng,B Cakar,P Lavere,J Cao,J Yao,P Singh,JT Lei,JA Toonen,S Haricharan,M Anurag,K Shah,M Kavuri,DW Chan,X Chen,DH Gutmann,CE Foulds,MJ Ellis,EC Chang
DOI: https://doi.org/10.1158/1538-7445.sabcs16-p1-08-01
IF: 11.2
2017-01-01
Cancer Research
Abstract:Abstract Background. Although great strides have been made in targeting the ER pathway for treating ER+ breast cancer, relapse and death is common and is closely linked to resistance to ER-targeting agents. As a result, the majority of deaths from breast cancer still come from ER+ tumors. To discover drivers for endocrine resistance, we have sequenced tumor DNAs from a cohort of >600 patients treated with 5-year tamoxifen (Tam) monotherapy with a median 10.4 years follow up. Our preliminary data show that the worst outcome mutations (Hazard Ratio of ∼3 for relapse) were mostly those of the Neurofibromatosis type 1 (NF1) gene (encoding Neurofibromin), with nonsense/frame shift mutations creating early stop codons. Germline NF1mutations cause neurofibromatosis type 1, a common inherited disorder that predisposes individuals to both benign and malignant tumors of the nervous system, as well as an increased risk for breast cancer. Analysis of DNA sequencing data has also shown that the NF1 gene is mutated in a wide range of common cancers (e.g., melanoma, lymphoma, and cancers of the lung, breast, and colon). Thus, NF1-deficiency underlies the formation and/or progression of a large number of cancers, so that the development of therapies targeted to NF1-deficient malignancies would have broad impact. These observations support the hypothesis that NF1 gene inactivation is associated with aggressive tumor behaviors, such as endocrine therapy resistance in breast cancer. The key focus of this study is to define how the NF1 protein neurofibromin, regulates endocrine therapy resistance. Although neurofibromin is best known as a negative regulator for Ras, our data show that it may have other functions. Method. Our data suggest that many of the identified nonsense/frame shift create a NF1 null state; thus, we have used gene-silencing to recapitulate the effects of such NF1 mutations on the activities of ER+ breast cancer cells. NF1+ and NF1– ER+ breast cancer cells were grown in defined media to measure how estradiol (E2) and Tam impact their growth, transforming activities, and gene expression. The binding between neurofibromin and components of the ER transcriptional pathway was measured biochemically and using the mammalian two-hybrid system. Results. Our data showed that NF1-silenced cells use Tam as an agonist and can grow with very little E2, and these activities are driven by enhanced recruitment of ER to the ERE, leading to efficient expression of many classic ER-responsive genes. Expressing the NF1-GAP domain does not restore normal responses to Tam and E2 in NF1-silenced cells, suggesting that neurofibromincan regulate ER activity in a Ras-independent manner. To investigate the possibility that neurofibromin can directly regulate ER, we found that it can bind ER; furthermore, neurofibromin was more strongly recruited to the ERE by Tam than by E2. Conclusion. Our data support a model whereby neurofibromin acts like a co-repressor for ER. As such,NF1 loss may result in more aggressive tumor behaviors by activating, not only the Ras pathways, but also the ER transcriptional pathways. Simultaneous activation of two powerful oncogenic pathways by the loss of a single tumor suppressor may explain why neurofibromin is such a potent tumor suppressor lost in a wide range of cancers. Citation Format: Zheng Z-Y, Cakar B, Lavere P, Cao J, Yao J, Singh P, Lei JT, Toonen JA, Haricharan S, Anurag M, Shah K, Kavuri M, Chan DW, Chen X, Gutmann DH, Foulds CE, Ellis MJ, Chang EC. Regulation of estrogen receptor-α by NF1 [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-08-01.
-
Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers
Jayanthi P. Gudikote,Tina Cascone,Alissa Poteete,Piyada Sitthideatphaiboon,Qiuyu Wu,Naoto Morikawa,Fahao Zhang,Shaohua Peng,Pan Tong,Lerong Li,Li Shen,Monique Nilsson,Phillip Jones,Erik P. Sulman,Jing Wang,Jean-Christophe Bourdon,Faye M. Johnson,John V. Heymach
DOI: https://doi.org/10.1016/j.jbc.2021.101163
IF: 5.485
2021-01-01
Journal of Biological Chemistry
Abstract:Inactivation of p53 is present in almost every tumor, and hence, p53-reactivation strategies are an important aspect of cancer therapy. Common mechanisms for p53 loss in cancer include expression of p53-negative regulators such as MDM2, which mediate the degradation of wildtype p53 (p53α), and inactivating mutations in the TP53 gene. Currently, approaches to overcome p53 deficiency in these cancers are limited. Here, using non-small cell lung cancer and glioblastoma multiforme cell line models, we show that two alternatively spliced, functional truncated isoforms of p53 (p53β and p53γ, comprising exons 1 to 9β or 9γ, respectively) and that lack the C-terminal MDM2-binding domain have markedly reduced susceptibility to MDM2-mediated degradation but are highly susceptible to nonsense-mediated decay (NMD), a regulator of aberrant mRNA stability. In cancer cells harboring MDM2 overexpression or TP53 mutations downstream of exon 9, NMD inhibition markedly upregulates p53β and p53γ and restores activation of the p53 pathway. Consistent with p53 pathway activation, NMD inhibition induces tumor suppressive activities such as apoptosis, reduced cell viability, and enhanced tumor radiosensitivity, in a relatively p53-dependent manner. In addition, NMD inhibition also inhibits tumor growth in a MDM2-overexpressing xenograft tumor model. These results identify NMD inhibition as a novel therapeutic strategy for restoration of p53 function in p53-deficient tumors bearing MDM2 overexpression or p53 mutations downstream of exon 9, subgroups that comprise approximately 6% of all cancers.
-
Abstract 830: ZFP14, a p53 target, suppresses tumor formation by regulating HOXA gene cluster expression
Shakur Mohibi,Jin Zhang,Mingyi Chen,Xinbin Chen
DOI: https://doi.org/10.1158/1538-7445.am2022-830
IF: 11.2
2022-01-01
Cancer Research
Abstract:Abstract KRAB containing zinc finger proteins form the largest class of mammalian transcription factors. However, the physiological or pathological functions of the majority of them are unknown. Here, we established ZFP14 as a p53 target gene that is induced upon genotoxic stress in a p53-dependent manner. To determine the function of ZFP14 in mouse and human cancer cell lines, we generated ZFP14-KO cells that showed increased senescence as well as reduced cell growth and migration. Moreover, we showed that ZFP14 negatively regulates p53, which was the cause of reduced oncogenic properties in ZFP14-KO cancer cells. Mechanistically, we found that ZFP14 modulates p53 protein stability by associating with and possibly enhancing MDM2/p53 complex integrity through its zinc finger domains. Interestingly, we found that lower expression of ZFP14 correlates with poor patient survival in multiple human cancers. Notably, in a similar fashion, mice deficient in ZFP14 were susceptible to spontaneous tumor formation, developed other abnormalities such as systemic inflammation and liver steatosis, which led to their shorter lifespan. Finally, we showed that ZFP14 regulates the expression of the HOXA gene cluster in mouse and humans, which we propose as a possible mechanism by which ZFP14 regulates tumorigenesis. Our findings suggest that ZFP14 is an important regulator of p53 and HOXA genes during inflammation and tumorigenesis. Citation Format: Shakur Mohibi, Jin Zhang, Mingyi Chen, Xinbin Chen. ZFP14, a p53 target, suppresses tumor formation by regulating HOXA gene cluster expression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 830.
-
Inhibition Of Tumor Suppressor P73 By Nerve Growth Factor Receptor Via Chaperone-Mediated Autophagy
Daniel Nguyen,Kun Yang,Lucia Chao,Yun Deng,Xiang Zhou,Zhen Zhang,Shelya X Zeng,Hua Lu
DOI: https://doi.org/10.1093/jmcb/mjaa017
2020-01-01
Journal of Molecular Cell Biology
Abstract:The tumor suppressr p73 is a homolog of p53 and is capable of inducing cell cycle arrest and apoptosis. Here, we identify nerve growth factor receptor (NGFR, p75NTR, or CD271) as a novel negative p73 regulator. p73 activates NGFR transcription, which, in turn, promotes p73 degradation in a negative feedback loop. NGFR directly binds to p73 central DNA-binding domain and suppresses p73 transcriptional activity as well as p73-mediated apoptosis in cancer cells. Surprisingly, we uncover a previously unknown mechanism of NGFR-facilitated p73 degradation through the chaperone-mediated autophagy (CMA) pathway. Collectively, our studies demonstrate a new oncogenic function for NGFR in inactivating p73 activity by promoting its degradation through the CMA.
-
Novel Roles For P53 In The Genesis And Targeting Of Tetraploid Cancer Cells
Batzaya Davaadelger,Hong Shen,Carl G Maki
DOI: https://doi.org/10.1371/journal.pone.0110844
IF: 3.7
2014-01-01
PLoS ONE
Abstract:Tetraploid (4N) cells are considered important in cancer because they can display increased tumorigenicity, resistance to conventional therapies, and are believed to be precursors to whole chromosome aneuploidy. It is therefore important to determine how tetraploid cancer cells arise, and how to target them. P53 is a tumor suppressor protein and key regulator of tetraploidy. As part of the "tetraploidy checkpoint", p53 inhibits tetraploid cell proliferation by promoting a G1-arrest in incipient tetraploid cells (referred to as a tetraploid G1 arrest). Nutlin-3a is a preclinical drug that stabilizes p53 by blocking the interaction between p53 and MDM2. In the current study, Nutlin-3a promoted a p53-dependent tetraploid G1 arrest in two diploid clones of the HCT116 colon cancer cell line. Both clones underwent endoreduplication after Nutlin removal, giving rise to stable tetraploid clones that showed increased resistance to ionizing radiation (IR) and cisplatin (CP)-induced apoptosis compared to their diploid precursors. These findings demonstrate that transient p53 activation by Nutlin can promote tetraploid cell formation from diploid precursors, and the resulting tetraploid cells are therapy (IR/CP) resistant. Importantly, the tetraploid clones selected after Nutlin treatment expressed approximately twice as much P53 and MDM2 mRNA as diploid precursors, expressed approximately twice as many p53-MDM2 protein complexes (by co-immunoprecipitation), and were more susceptible to p53-dependent apoptosis and growth arrest induced by Nutlin. Based on these findings, we propose that p53 plays novel roles in both the formation and targeting of tetraploid cells. Specifically, we propose that 1) transient p53 activation can promote a tetraploid-G1 arrest and, as a result, may inadvertently promote formation of therapy-resistant tetraploid cells, and 2) therapy-resistant tetraploid cells, by virtue of having higher P53 gene copy number and expressing twice as many p53-MDM2 complexes, are more sensitive to apoptosis and/or growth arrest by anti-cancer MDM2 antagonists (e.g. Nutlin).
-
Distinct functions of wild-type and R273H mutant Δ133p53α differentially regulate glioblastoma aggressiveness and therapy-induced senescence
Sebastien M. Joruiz,Natalia Von Muhlinen,Izumi Horikawa,Mark R. Gilbert,Curtis C. Harris
DOI: https://doi.org/10.1038/s41419-024-06769-5
2024-06-27
Cell Death and Disease
Abstract:Despite being mutated in 92% of TP53 mutant cancers, how mutations on p53 isoforms affect their activities remain largely unknown. Therefore, exploring the effect of mutations on p53 isoforms activities is a critical, albeit unexplored area in the p53 field. In this article, we report for the first time a mutant Δ133p53α-specific pathway which increases IL4I1 and IDO1 expression and activates AHR, a tumor-promoting mechanism. Accordingly, while WT Δ133p53α reduces apoptosis to promote DNA repair, mutant R273H also reduces apoptosis but fails to maintain genomic stability, increasing the risks of accumulation of mutations and tumor's deriving towards a more aggressive phenotype. Furthermore, using 2D and 3D spheroids culture, we show that WT Δ133p53α reduces cell proliferation, EMT, and invasion, while the mutant Δ133p53α R273H enhances all three processes, confirming its oncogenic potential and strongly suggesting a similar in vivo activity. Importantly, the effects on cell growth and invasion are independent of mutant full-length p53α, indicating that these activities are actively carried by mutant Δ133p53α R273H. Furthermore, both WT and mutant Δ133p53α reduce cellular senescence in a senescence inducer-dependent manner (temozolomide or radiation) because they regulate different senescence-associated target genes. Hence, WT Δ133p53α rescues temozolomide-induced but not radiation-induced senescence, while mutant Δ133p53α R273H rescues radiation-induced but not temozolomide-induced senescence. Lastly, we determined that IL4I1, IDO1, and AHR are significantly higher in GBMs compared to low-grade gliomas. Importantly, high expression of all three genes in LGG and IL4I1 in GBM is significantly associated with poorer patients' survival, confirming the clinical relevance of this pathway in glioblastomas. These data show that, compared to WT Δ133p53α, R273H mutation reorientates its activities toward carcinogenesis and activates the oncogenic IL4I1/IDO1/AHR pathway, a potential prognostic marker and therapeutic target in GBM by combining drugs specifically modulating Δ133p53α expression and IDO1/Il4I1/AHR inhibitors.
cell biology
-
Neurogenic differentiation factor 1 promotes colorectal cancer cell proliferation and tumorigenesis by suppressing the p53/p21 axis
Ke Lei,Wenfang Li,Can Huang,Yanjun Li,Leader Alfason,Hezhao Zhao,Makoto Miyagishi,Shourong Wu,Vivi Kasim
DOI: https://doi.org/10.1111/cas.14233
IF: 5.7
2019-12-10
Cancer Science
Abstract:<p>Neurogenic differentiation factor 1 (NeuroD1) is a transcription factor critical for promoting neuronal differentiation and maturation. NeuroD1 is involved in neuroblastoma and medulloblastoma, however, its molecular mechanism in promoting tumorigenesis remains unclear. Furthermore, the role of NeuroD1 in non‐neural malignancies has not been widely characterized. Here, we found that <i>NeuroD1</i> is highly expressed in colorectal cancer. <i>NeuroD1</i>‐silencing induces the expression of p21, a master regulator of the cell cycle, leading to G<sub>2</sub>‐M phase arrest and suppression of colorectal cancer cell proliferation as well as colony formation potential. Moreover, NeuroD1‐mediated regulation of p21 expression occurs in a p53‐dependent manner. Through chromatin immunoprecipitation and point mutation analysis in the predicted NeuroD1 binding site of the <i>p53</i> promoter, we found that NeuroD1 directly binds to the <i>p53</i> promoter and suppresses its transcription, resulting in increased p53 expression in <i>NeuroD1</i>‐silenced colorectal cancer cells. Finally, xenograft experiments demonstrated that <i>NeuroD1</i>‐silencing suppresses colorectal cancer cell tumorigenesis potential by modulating p53 expression. These findings reveal NeuroD1 as a novel regulator of the p53/p21 axis, underscoring its importance in promoting non‐neural malignancies. Furthermore, this study provides insight into the transcriptional regulation of p53.</p>
oncology
-
Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells
Kamil Lisek,Elena Campaner,Yari Ciani,Dawid Walerych,Giannino Del Sal
DOI: https://doi.org/10.18632/oncotarget.24974
2018-04-17
Oncotarget
Abstract:NRF2 (NFE2L2) is one of the main regulators of the antioxidant response of the cell. Here we show that in cancer cells NRF2 targets are selectively upregulated or repressed through a mutant p53-dependent mechanism. Mechanistically, mutant p53 interacts with NRF2, increases its nuclear presence and resides with NRF2 on selected ARE containing gene promoters activating the transcription of a specific set of genes while leading to the transcriptional repression of others. We show that thioredoxin (<i>TXN)</i> is a mutant p53-activated NRF2 target with pro-survival and pro-migratory functions in breast cancer cells under oxidative stress, while heme oxygenase 1 (<i>HMOX1)</i> is a mutant p53-repressed target displaying opposite effects. A gene signature of NRF2 targets activated by mutant p53 shows a significant association with bad overall prognosis and with mutant p53 status in breast cancer patients. Concomitant inhibition of thioredoxin system with Auranofin and of mutant p53 with APR-246 synergizes in killing cancer cells expressing p53 gain-of-function mutants.
-
Wild-type p53 inhibits pro-invasive properties of TGF-β3 in breast cancer, in part through regulation of EPHB2, a new TGF-β target gene
Suzanne Lam,Eliza Wiercinska,Amina F. A. S. Teunisse,Kirsten Lodder,Peter ten Dijke,Aart G. Jochemsen
DOI: https://doi.org/10.1007/s10549-014-3147-8
2014-01-01
Breast Cancer Research and Treatment
Abstract:The p53 tumor suppressor protein is primarily known for its important role in tumor suppression. In addition, p53 affects tumor cell migration, invasion, and epithelial-mesenchymal transition (EMT); processes also regulated by the transforming growth factor-β (TGF-β) signaling pathway. Here, we investigated the role of p53 in breast tumor cell invasion, migration, and EMT and examined the interplay of p53 with TGF-β3 in these processes. MCF-10A1 and MCF-10CA1a breast cancer cells were treated with Nutlin-3 and TGF-β3, and the effects on tumor cell migration and invasion were studied in transwell and 3D spheroid invasion assays. The effects of Nutlin-3 and TGF-β3 on EMT were examined in NMuMG cells. To identify genes involved in TGF-β-induced invasion that are modulated by p53, a Human Tumor Metastasis-specific RT-PCR array was performed. Verification of EPHB2 regulation by TGF-β3 and p53 was performed on breast cancer tumor cell lines. We demonstrate that p53 inhibits basal and TGF-β3-induced invasion, migration, and EMT in normal breast epithelial and breast cancer cells. Pharmacological activation of p53 inhibited induction of several TGF-β3 targets involved in TGF-β3-induced tumor cell invasion, i.e., matrix metallo proteinase (MMP)2 , MMP9 , and integrin β 3 . The ephrin-type B receptor 2 (EPHB2) gene was identified as a new TGF-β target important for TGF-β3-mediated invasion and migration, whose transcriptional activation by TGF-β3 is also inhibited by p53. The results show an intricate interplay between p53 and TGF-β3 whereby p53 inhibits the TGF-β3-induced expression of genes, e.g., EPHB2, to impede tumor cell invasion and migration.
-
Master regulator: p53's pivotal role in steering NK-cell tumor patrol
Haohao Wang,Qingjie Chen,Qinghua Liu,Changjiang Luo
DOI: https://doi.org/10.3389/fimmu.2024.1428653
2024-08-09
Abstract:The p53 protein, encoded by TP53, is a tumor suppressor that plays a critical role in regulating apoptosis, cell cycle regulation, and angiogenesis in tumor cells via controlling various downstream signals. Natural killer (NK) cell-mediated immune surveillance is a vital self-defense mechanism against cancer and other diseases, with NK cell activity regulated by various mechanisms. Among these, p53 plays a significant role in immune regulation by maintaining the homeostasis and functionality of NK cells. It enhances the transcriptional activity of NK cell-activating ligands and downregulates inhibitory ligands to boost NK cell activation and tumor-killing efficacy. Additionally, p53 influences NK cell cytotoxicity by promoting apoptosis, autophagy, and ferroptosis in different tumor cells. p53 is involved in the regulation of NK cell activity and effector functions through multiple pathways. p53 also plays a pivotal role in the tumor microenvironment (TME), regulating the activity of NK cells. NK cells are critical components of the TME and are capable of directly killing tumor cells. And p53 mutates in numerous cancers, with the most common alteration being a missense mutation. These mutations are commonly associated with poor survival rates in patients with cancer. This review details p53's role in NK cell tumor immunosurveillance, summarizing how p53 enhances NK cell recognition and tumor destruction. We also explore the potential applications of p53 in tumor immunotherapy, discussing strategies for modulating p53 to enhance NK cell function and improve the efficacy of tumor immunotherapy, along with the associated challenges. Understanding the interaction between p53 and NK cells within the TME is crucial for advancing NK cell-based immunotherapy and developing p53-related novel therapeutics.
-
p53 missense mutant G242A subverts natural killer cells in sheltering mouse breast cancer cells against immune rejection
Mohammad B. Uddin,Kartik R. Roy,Ronald A. Hill,Sagor C. Roy,Xin Gu,Li Li,Qian-Jin Zhang,Zongbing You,Yong-Yu Liu
DOI: https://doi.org/10.1016/j.yexcr.2022.113210
IF: 4.145
2022-08-01
Experimental Cell Research
Abstract:Cancer cells acquire immunoediting ability to evade immune surveillance and thus escape eradication. It is widely known that mutant proteins encoded from tumor suppressor TP53 exhibit gain-of-function in cancer cells, thereby promoting progression; however, how mutant p53 contributes to the sheltering of cancer cells from host anticancer immunity remains unclear. Herein, we report that murine p53 missense mutation G242A (corresponding to human G245A) suppresses the activation of host natural killer (NK) cells, thereby enabling breast cancer cells to avoid immune assault. We found that serial injection of EMT6 breast cancer cells that carry wild-type (wt) Trp53, like normal fibroblasts, promoted NK activity in mice, while SVTneg2 cells carrying Trp53 G242A+/+ mutation decreased NK cell numbers and increased CD8+ T lymphocyte numbers in spleen. Innate immunity based on NK cells and CD8 T cells was reduced in p53 mutant-carrying transgenic mice (Trp53 R172H/+, corresponding to human R175H/+). Further, upon co-culture with isolated NK cells, EMT6 cells substantively activated NK cells and proliferation thereof, increasing interferon-gamma (IFN-γ) production; however, SVTneg2 cells suppressed NK cell activation. Further mechanistic study elucidated that p53 can modulate expression by cancer cells of Mult-1 and H60a, which are activating and inhibitory ligands for NKG2D receptors of NK cells, respectively, to enhance immune surveillance against cancer. Our findings demonstrate that wt p53 is requisite for NK cell-based immune recognition and elimination of cancerous cells, and perhaps more importantly, that p53 missense mutant presence in cancer cells impairs NK cell-attributable responses, thus veiling cancerous cells from host immunity and enabling cancer progression.
oncology,cell biology
-
Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway
Nannan Liu,Xinxiu Jiang,Leiming Guo,Chuchu Zhang,Meimei Jiang,Zhuoran Sun,Yizheng Zhang,Wunan Mi,Jiehan Li,Yang Fu,Feng Wang,Lingling Zhang,Yingjie Zhang
DOI: https://doi.org/10.7150/ijbs.67200
2022-01-01
International Journal of Biological Sciences
Abstract:The most frequent genetic alterations of the TP53 gene in human cancer were reported. TP53 mutation gains new function as a target of genetic instability, which is associated with increased tumor progression and poor survival rate in patients. In this study, more than three hundred colorectal cancer patients' samples were firstly analyzed, and the results showed that patients with mutant p53 had higher levels of AKT phosphorylation and PD-L1 expression, which were next verified both in cell lines in vitro and patients' samples in vivo. Further studies demonstrated that the hotspot of mutant p53 directly binds to the promoter of PHLPP2 to inhibit its transcription, and resulting in down-regulating its protein expressional level. Subsequently, AKT was released and activated, promoting tumor proliferation and metastasis. In parallel, 4EBP1/eIF4E was identified as downstream executors of AKT to enhance the translational level of PD-L1, which decreased the activation of T cells. Besides, inhibiting AKT/mTOR pathway significantly suppressed PD-L1 expression, tumor growth, and immune escape in p53 mutated cells. In conclusion, mutant p53 achieved its Gain-of-Function by transcriptionally inhibiting PHLPP2 and activating AKT, which suppresses immune response and advances tumor growth. Thus, this study provides an excellent basis for a further understanding of the clinical treatment of neoplastic diseases for patients with mutant p53, with an emphasis on immunotherapy.
biochemistry & molecular biology
-
Abstract PR-002: Uncovering novel therapeutic avenues for glioma by exploring the functional interplay of FGFR1, p53, and ribosome biogenesis
Asimina Zisi,Ewelina Dratkiewicz,Dimitris C. Kanellis,Simon Moussaud,Ida Karlsson,Helena Carén,Lars Bräutigam,Jiri Bartek,Mikael S. Lindström
DOI: https://doi.org/10.1158/1538-7445.brain23-pr-002
IF: 11.2
2024-03-05
Cancer Research
Abstract:High-grade gliomas (HGGs) are known for their aggressive nature and resistance to chemotherapy, resulting in a poor prognosis and a pressing need to identify new molecular targets and dependencies. Ribosome biogenesis (RiBi) has emerged as a promising target since many cancer types, including HGGs, rely on high RiBi rates to sustain proliferation. In a previous study, we evaluated the effects of BMH-21, a non-genotoxic small molecule p53 inducer that preferentially blocks RNA pol I transcription, perturbs RiBi, and triggers nucleolar stress (Zisi A et al., Neuro Oncol, 2023). We tested BMH-21 in adult and pediatric HGG cell lines and a zebrafish transplant model. Treatment with BMH-21 reduced glioma cell viability, activated cell death programs, and impaired growth of transplanted HGG cells in zebrafish. A chemical synergy screen with BMH-21 revealed synergistic effects among inhibitors of the Fibroblast Growth Factor Receptor (FGFR) pathway, such as Erdafitinib, suggesting its involvement in the cellular responses triggered by BMH-21. Indeed, FGF2 showed nucleolar localization that was altered by BMH-21, which also induced FGF2 expression, secretion, and FGFR1 activation with downstream effects on the SOX2 levels (Zisi A et al., Neuro Oncol, 2023). These effects were consistently observed using other RNA pol I inhibitors or siRNA-based genetic depletion of POLR1A, underlining a mechanistic interplay that remains to be elucidated. FGFR1 is amplified or mutated in various pediatric brain tumors, thus a candidate for targeted therapies. We noted that BMH-21 while activating the FGFR1 pathway, eventually suppressed FGFR1 protein levels, but this was not consistently seen in all cell lines tested, a finding we here investigated further, being a potentially important aspect of FGFR1 targeting. Our new data show that following BMH-21 treatment, FGFR1 protein was markedly downregulated in wild-type p53 glioma lines. Other non-genotoxic p53-activating small molecules such as Curaxin CBL0137 and Nutlin-3a also markedly reduced FGFR1. siRNA-based p53 depletion prevented FGFR1 protein suppression in response to BMH-21 or Nutlin-3a. While Erdafitinib had modest growth inhibitory effects as monotherapy, its combination with Nutlin-3a displayed potent anti-proliferative effects in wt p53 glioma cell lines. In summary, FGFR1 emerges as a target of p53-dependent repression in glioma cells, analogous to the repressive effects that p53 has on other amplified oncogenes. Our data supports the design of FGFRi-based combination therapies with non-genotoxic p53 inducers and RiBi inhibitors while considering p53 status, and clearly warrants further testing against HGG. Citation Format: Asimina Zisi, Ewelina Dratkiewicz, Dimitris C. Kanellis, Simon Moussaud, Ida Karlsson, Helena Carén, Lars Bräutigam, Jiri Bartek, Mikael S. Lindström. Uncovering novel therapeutic avenues for glioma by exploring the functional interplay of FGFR1, p53, and ribosome biogenesis [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1) nr PR-002.
oncology
-
RNF216 Alleviates Radiation-Induced Apoptosis and DNA Damage Through Regulating Ubiquitination-Mediated Degradation of p53 in Glioblastoma
Songwang Xie,Zhen Hong,Yan Li,Junyong Wang,Jian Wang,Shaoquan Li,Yongchang Liu
DOI: https://doi.org/10.1007/s12035-022-02868-6
IF: 5.682
2022-05-21
Molecular Neurobiology
Abstract:Glioblastoma (GBM) is the most common and lethal subtype of glioma, characterized by uncontrolled cancer cell proliferation, extensive infiltration, and therapeutic resistance. Ring finger protein 216 (RNF216) is a RING-type E3 ubiquitin ligase aberrantly expressed in multiple human cancers. Tumor protein 53 (p53) is a transcription factor that acts as a tumor suppressor. This study aimed to compare the RNF216 expression in GBM tissues and normal peritumoral tissues and to examine the effects of RNF216 overexpression/knockdown on tumorigenesis, radioresistance, and the p53 pathway in GBM. The results showed that RNF216 was overexpressed in GBM tissues and cell lines, and high RNF216 expression was related to a poor prognosis. RNF216 overexpression promoted GBM cell growth and inhibited apoptosis, while RNF216 knockdown impaired GBM cell growth and enhanced cell death. RNF216 was also highly expressed in recurrent GBM tissues compared with paired primary tumors. The upregulation of RNF216 not only facilitated GBM cell growth but also protected cells against X-ray irradiation-induced apoptosis and DNA damage, while RNF216 knockdown exerted opposite effects. Moreover, the implantation of GBM cells with RNF216 silencing suppressed tumorigenesis and increased radiosensitivity of mice bearing GBM xenografts. Further analysis revealed that RNF216 overexpression reduced the stability of p53 protein via ubiquitination and negatively regulated the p53 pathway, while RNF216 knockdown preserved the p53 protein. In conclusion, RNF216 effectively attenuated radiation-induced apoptosis and DNA damage in GBM via inducing ubiquitination-mediated degradation of p53. These findings suggest the potential therapeutic use of RNF216 inhibition for tumorigenesis and therapeutic resistance in GBM.
neurosciences
-
Abstract 638: FGFR4 mediates nuclear accumulation of NRF2 by binding to P62 in gastric cancer
Nadeem S. Bhat,Mohammed Soutto,Xing Zhang,Zheng Chen,Shoumin Zhu,Selma Maacha,Melanie Genoula,Dunfa Peng,Heng Lu,Oliver G McDonald,Xi Steven Chen,Longlong Cao,Zekuan Xu,Wael El-Rifai
DOI: https://doi.org/10.1158/1538-7445.am2024-638
IF: 11.2
2024-03-31
Cancer Research
Abstract:Background: Helicobacter pylori (H. pylori) is the major cause of gastric cancer. Fibroblast growth factor receptor 4 (FGFR4) is a member of the highly conserved tyrosine kinase family known to be activated in cancer. Nuclear Factor Erythroid 2-Related Factor 2 (NRF2), a transcription factor, is essential for the antioxidant response and exhibits cytoprotective properties against cellular stress and oxidative damage. This study investigates the novel functions of FGFR4 and its role in regulating the antioxidant response in gastric tumorigenesis. Methods: We used public datasets, gastric tissues from mice and human, and gastric cancer cell lines. In vitro and in vivo H. pylori infections were performed. Western blot, RT-qPCR, Immunofluorescence, flow cytometry, Immunohistochemistry, Immunoprecipitation, Proximity ligation assay and Luciferase reporter assays were performed. Results: The analysis of a public dataset revealed that overexpression of FGFR4 is associated with an oxidative stress signature and poor survival. Gene set enrichment analysis (GSEA) showed that tissue samples with high FGFR4 levels had an enrichment of NRF2 signature genes. In vitro cell models infected with H. pylori showed an increase in reactive oxygen species (ROS). Knockdown of FGFR4 resulted in significant reductions in NRF2 protein and transcriptional activity, leading to increased ROS levels and DNA damage. Immunofluorescence analysis using various models confirmed that FGFR4 knockdown reversed the accumulation of NRF2 in the nucleus. Dysplastic and neoplastic gastric lesions in the TFF1-KO mouse model exhibited high levels of both FGFR4 and NRF2. Pharmacologic inhibition or knockdown of FGFR4 significantly decreased NRF2 levels, as well as the size and number of gastric cancer spheroids. Mechanistically, elevated levels of P62 protein were associated with FGFR4 expression. Binding between FGFR4 and P62 proteins, which competes with NRF2-KEAP1 interaction, was detected using immunoprecipitation and proximity ligation assay. Immunohistochemistry analysis on a tissue microarray showed increased FGFR4 immunostaining in HGD/Cancer samples compared to adjacent normal samples, and this increase correlated with an increase in NRF2 and P62 levels. Conclusion: These findings revealed that FGFR4 has a distinct functional role in promoting gastric carcinogenesis. FGFR4 binds to P62 to inhibit the interaction between NRF2 and KEAP1, allowing NRF2 to avoid degradation facilitating its translocation and accumulation in the nucleus. The use of FGFR4 inhibitors is a viable treatment option that warrants further research in patients with gastric cancer. Citation Format: Nadeem S. Bhat, Mohammed Soutto, Xing Zhang, Zheng Chen, Shoumin Zhu, Selma Maacha, Melanie Genoula, Dunfa Peng, Heng Lu, Oliver G McDonald, Xi Steven Chen, Longlong Cao, Zekuan Xu, Wael El-Rifai. FGFR4 mediates nuclear accumulation of NRF2 by binding to P62 in gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 638.
oncology
-
IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
Alexander Thiem,Sonja Hesbacher,Hermann Kneitz,Teresa di Primio,Markus V. Heppt,Heike M. Hermanns,Matthias Goebeler,Svenja Meierjohann,Roland Houben,David Schrama
DOI: https://doi.org/10.1186/s13046-019-1403-9
2019-09-11
Abstract:Abstract Background Immune checkpoint inhibition and in particular anti-PD-1 immunotherapy have revolutionized the treatment of advanced melanoma. In this regard, higher tumoral PD-L1 protein (gene name: CD274 ) expression is associated with better clinical response and increased survival to anti-PD-1 therapy . Moreover, there is increasing evidence that tumor suppressor proteins are involved in immune regulation and are capable of modulating the expression of immune checkpoint proteins. Here, we determined the role of p53 protein (gene name: TP53 ) in the regulation of PD-L1 expression in melanoma. Methods We analyzed publicly available mRNA and protein expression data from the cancer genome/proteome atlas and performed immunohistochemistry on tumors with known TP53 status. Constitutive and IFN-ɣ-induced PD-L1 expression upon p53 knockdown in wildtype, TP53 -mutated or JAK2-overexpressing melanoma cells or in cells, in which p53 was rendered transcriptionally inactive by CRISPR/Cas9, was determined by immunoblot or flow cytometry. Similarly, PD-L1 expression was investigated after overexpression of a transcriptionally-impaired p53 (L22Q, W23S) in TP 53-wt or a TP53 -knockout melanoma cell line. Immunoblot was applied to analyze the IFN-ɣ signaling pathway. Results For TP53 -mutated tumors, an increased CD274 mRNA expression and a higher frequency of PD-L1 positivity was observed. Interestingly, positive correlations of IFNG mRNA and PD-L1 protein in both TP53 -wt and -mutated samples and of p53 and PD-L1 protein suggest a non-transcriptional mode of action of p53. Indeed, cell line experiments revealed a diminished IFN-ɣ-induced PD-L1 expression upon p53 knockdown in both wildtype and TP53 -mutated melanoma cells, which was not the case when p53 wildtype protein was rendered transcriptionally inactive or by ectopic expression of p53 L22Q,W23S , a transcriptionally-impaired variant, in TP53 -wt cells. Accordingly, expression of p53 L22Q,W23S in a TP53 -knockout melanoma cell line boosted IFN-ɣ-induced PD-L1 expression. The impaired PD-L1-inducibility after p53 knockdown was associated with a reduced JAK2 expression in the cells and was almost abrogated by JAK2 overexpression. Conclusions While having only a small impact on basal PD-L1 expression, both wildtype and mutated p53 play an important positive role for IFN-ɣ-induced PD-L1 expression in melanoma cells by supporting JAK2 expression. Future studies should address, whether p53 expression levels might influence response to anti-PD-1 immunotherapy.
oncology